[CAS NO. 2834087-69-1]  HIV-1 inhibitor-50

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2834087-69-1]

Catalog
HY-152160
Brand
MCE
CAS
2834087-69-1

DESCRIPTION [2834087-69-1]

Overview

MDL-
Molecular Weight427.43
Molecular FormulaC24H18FN5O2
SMILESCC1=C(OC2=C3COCC3=NC(NC4=CC(F)=C(C=C4)C#N)=N2)C(C)=CC(/C=C/C#N)=C1

For research use only. We do not sell to patients.

Summary

HIV-1 inhibitor-50 是一种非核苷逆转录酶抑制剂 ( NNRTI ),靶向 HIV-1 逆转录酶 ( RT ) ( IC 50 =50 nM)。 HIV-1 inhibitor-50 具有显著的抗病毒活性,对 HIV-1 IIIB 及其突变株的 EC 50 为 2.22-53.3 nM。


IC50 & Target

HIV-1 (WT)

3.04 nM (EC 50 )

HIV-1 (L100I)

3.04 nM (EC 50 )

HIV-1 (K103N)

2.87 nM (EC 50 )

HIV-1 (Y181C)

10.2 nM (EC 50 )

HIV-1 (Y188L)

13.2 nM (EC 50 )

HIV-1 (E138K)

9.77 nM (EC 50 )

HIV-1 (F227L+V106A)

19.8 nM (EC 50 )


In Vitro

HIV-1 inhibitor-50 (compound 36a) protects MT-4 cells from HIV-1 IIIB and RES056 with EC 50 s of 2.22 nM and 53.3 nM, respectively [1] .
HIV-1 inhibitor-50 inhibits MT-4 cells viability with an CC 50 value of 45.6 μM [1] .
HIV-1 inhibitor-50 (hydrochloride; ) shows a lower intrinsic clearance rates in microsomes (CL=87.6 μL/min/mg) and liver (CL=16.6 μL/min/mg), and leads to a higher metabolic stability (T 1/2 =11.3 min) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [1]

Cell Line: MT-4 cells
Concentration:
Incubation Time:
Result: Inhibited HIV-1 infection in MT-4 cells with EC 50 values of 3.04 nM (L100I), 2.87 nM (K103N), 10.2 nM (Y181C), 13.2 nM (Y188L), 9.77 nM (E138K), 19.8 nM (F227L+V106A), respectively.

In Vivo

HIV-1 inhibitor-50 (compound 36a) (hydrochloride; 2 mg/kg; i.v.; single dose) has a high clearance (CL=103 L/h/kg) and a modest half-life (T 1/2 =1.43 h) [1] .
HIV-1 inhibitor-50 (hydrochloride; 2000 mg/kg; p.o.; single dose) doesn’t result any abnormal behaviors or significant changes in body weight compared with the control in 7 days, indicating no acute toxicity [1] .

Pharmacokinetic Analysis [1]

Route Dose (mg/kg) T 1/2 (h) T max (h) C max (ng/mL) AUC 0-t (h·ng/mL) AUC 0-∞ (h·ng/mL) CL (L/h/kg) F (%)
i.v. 2 1.43 0 484 250 255 103 /
p.o. 10 5.12 0.25 37.5 107 154 / 12.1

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Please store the product under the recommended conditions in the Certificate of Analysis.